膵臓がん診断の世界市場レポート 2025年

膵臓がん診断市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.8％で63億8,000万米ドルに成長します。予測期間の成長は、リキッドバイオプシーの進歩、標的治療、診断における人工知能、個別化医療アプローチ、早期発見バイオマーカー、ネオアジュバント療法に起因すると考えられます。予測期間の世界の動向には、免疫療法調査、画像技術の進歩、外科手術の革新、国際共同研究イニシアティブ、ビッグデータ解析の統合などが含まれます。

膵臓がん診断市場の予想される成長は、膵臓がんの有病率の増加によって推進されると予想されます。膵臓組織における悪性細胞の開発を特徴とする膵臓がんは、主に喫煙、糖尿病、慢性膵炎、膵臓がんの家族歴、膵臓の炎症、特定の遺伝疾患などの要因に起因して、増加傾向にあります。膵臓がんを診断することは、治療方針を決定し、がんの病期を決定し、特定の腫瘍の特徴を特定し、治療成績を向上させ、患者のケアを最適化するために治療アプローチを調整するために極めて重要です。米国臨床腫瘍学会によると、2023年には米国で64,050人が膵がんと診断されると推定され、女性では8番目、男性では10番目に多いがんとなります。膵がんの新規症例発生率は、男女ともに年間約1％ずつ増加しています。その結果、膵臓がんの有病率の増加が膵臓がん診断市場拡大の重要な要因となっています。

ヘルスケア支出の増加は、膵臓がん診断市場の今後の成長に貢献しています。ヘルスケア支出には、特定の地域、国、組織内のヘルスケア部門に割り当てられる総財源が含まれます。この支出は、早期発見、正確な病期分類、タイムリーな介入を可能にする膵がん診断に向けられ、これらすべてが患者の転帰と生存率の向上を目指しています。例えば、2023年11月、カナダ保健情報研究所（Canadian Institute for Health Information）は、カナダの総医療費は2023年に3,440億米ドルに達する見込みであり、これは一人当たり8,740ドルに相当すると報告しました。これは、2022年の医療費が1.5％増にとどまった前年から2.8％増となり、ヘルスケア投資の大幅な回復を浮き彫りにしています。したがって、ヘルスケア支出の増加が膵臓がん診断市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膵臓がん診断 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の膵臓がん診断市場：成長率分析
• 世界の膵臓がん診断市場の実績：規模と成長, 2019-2024
• 世界の膵臓がん診断市場の予測：規模と成長, 2024-2029, 2034F
• 世界膵臓がん診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膵臓がん診断市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機器
• 消耗品
• サービス
• 世界の膵臓がん診断市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 化学療法
• 放射線治療
• 標的療法
• 世界の膵臓がん診断市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外分泌
• 腺がん
• 扁平上皮がん
• 腺扁平上皮がん
• コロイドがん
• 内分泌
• 世界の膵臓がん診断市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像検査
• 生検
• 血液検査
• ゲノム検査
• その他のテストの種類
• 世界の膵臓がん診断市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• がん研究センター
• 学術機関
• 外来手術センター
• その他のエンドユーザー
• 世界の膵臓がん診断市場、楽器のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イメージングシステム
• 生検装置
• 内視鏡機器
• 世界の膵臓がん診断市場消耗品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 試薬
• 生検針
• アッセイキット
• 世界の膵臓がん診断市場、サービスの種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断検査サービス
• ラボサービス
• コンサルティングサービス

第7章 地域別・国別分析

• 世界の膵臓がん診断市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膵臓がん診断市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膵臓がん診断市場：競合情勢
• 膵臓がん診断市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hitachi Medical Corporation Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories Inc.
• Danaher Corporation
• Siemens Healthcare GmbH
• FUJIFILM Corporation
• Becton Dickinson and Company
• Koninklijke Philips N.V.
• GE Healthcare Bio Sciences AB
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Illumina Inc.
• Qiagen Inc.
• Myriad Genetics Inc.
• Canon Medical Systems Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膵臓がん診断市場2029：新たな機会を提供する国
• 膵臓がん診断市場2029：新たな機会を提供するセグメント
• 膵臓がん診断市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pancreatic cancer diagnostics involve the procedures and techniques employed to identify, classify, and stage pancreatic cancer, aiming to ascertain the condition's nature, assess disease severity, and guide treatment decisions. This diagnostic approach is commonly applied to address different types of pancreatic cancer, including adenocarcinoma, squamous cell carcinoma, and insulinoma.

The primary categories of pancreatic cancer diagnostic products comprise instruments, consumables, and services. Instruments refer to tools or devices utilized to perform specific tasks or achieve desired outcomes during diagnostic procedures, often involving the manipulation or examination of biological tissue. Various treatment modalities, such as surgery, chemotherapy, radiation therapy, and targeted therapy, are employed to address different types of pancreatic cancer, including exocrine, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, colloid carcinoma, and endocrine. Diagnostic tests encompass a range of methods, including imaging tests, biopsies, blood tests, genomic tests, among others. These tests are utilized by diverse end-users, including hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and other healthcare facilities.

The pancreatic cancer diagnostic market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer diagnostic market statistics, including pancreatic cancer diagnostic industry global market size, regional shares, competitors with a pancreatic cancer diagnostic market share, detailed pancreatic cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer diagnostic industry. This pancreatic cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer diagnostic market size has grown strongly in recent years. It will grow from $4.24 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to growing genomic and molecular profiling, chemotherapy developments, radiation therapy refinements, research on pancreatic cancer genetics, awareness campaigns, and early detection efforts

The pancreatic cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $6.38 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to liquid biopsy advancements, targeted therapies, artificial intelligence in diagnostics, personalized medicine approaches, early detection biomarkers, and neoadjuvant therapies. Major trends in the forecast period include immunotherapy research, advancements in imaging technologies, surgical innovations, global collaborative research initiatives, and integration of big data analytics.

The anticipated growth in the pancreatic cancer diagnostic market is expected to be propelled by the increasing prevalence of pancreatic cancer. Pancreatic cancer, characterized by the development of malignant cells in the pancreas tissues, is on the rise, primarily attributed to factors such as smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, inflammation of the pancreas, and certain genetic disorders. Diagnosing pancreatic cancer is crucial for guiding treatment decisions, determining the cancer stage, identifying specific tumor characteristics, and tailoring treatment approaches to enhance outcomes and optimize patient care. According to the American Society of Clinical Oncology in 2023, it is estimated that 64,050 individuals in the United States will be diagnosed with pancreatic cancer, making it the eighth most common cancer in women and the tenth most common in men. The incidence of new cases of pancreatic cancer has been increasing by about 1% per year in both men and women. Consequently, the growing prevalence of pancreatic cancer is a significant driver behind the expansion of the pancreatic cancer diagnostic market.

The rising healthcare spending is contributing to the growth of the pancreatic cancer diagnostic market moving forward. Healthcare spending encompasses the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending is directed toward pancreatic cancer diagnostics to enable early detection, accurate staging, and timely intervention, all of which aim to enhance patient outcomes and survival rates. For example, in November 2023, the Canadian Institute for Health Information reported that total health spending in Canada is expected to reach $344 billion in 2023, which equates to $8,740 per person. This represents a 2.8% increase from the previous year, when health spending grew by only 1.5% in 2022, highlighting a significant rebound in healthcare investment. Therefore, the increase in healthcare spending is driving the growth of the pancreatic cancer diagnostic market.

Product innovations stand out as a prominent trend gaining traction in the pancreatic cancer diagnostic market, with companies actively adopting innovative solutions to maintain their competitive positions. One noteworthy example is the introduction of Prestige Biopharma Limited's first-in-class PAUF-detecting diagnostic kit in March 2023. This diagnostic tool is designed for the early detection of pancreatic cancer, leveraging the identification of PAUF (Pancreatic Adenocarcinoma Upregulated Factor), a unique tumor-specific biomarker associated with early metastasis and prevalent in approximately 80% of pancreatic cancer cases. The innovative diagnostic technique exhibits high sensitivity and specificity in identifying PAUF, with preliminary studies indicating nearly a 1.9 times higher expression level of PAUF in the blood plasma of pancreatic cancer patients compared to healthy individuals, as reported by Prestige Biopharma's Innovative Discovery Center.

A focus on developing screening tests for pancreatic cancer is another notable strategy among major companies in the pancreatic cancer diagnostic market. Screening tests are designed to detect the presence of pancreatic cancer at an early, asymptomatic stage, enabling timely intervention and improving treatment outcomes. An example is the N-NOSE plus Pancreas test launched by Hirotsu Bio Science in December 2022. This test, marketed directly to consumers in Japan, utilizes the olfactory senses of nematodes, tiny worms, for pancreatic cancer detection.

In January 2024, Bristol-Myers Squibb (BMS), a US-based biopharmaceutical company, announced its acquisition of Mirati Therapeutics, Inc. for $4.8 billion. This strategic move bolsters BMS's portfolio by incorporating Mirati's innovative cancer treatment assets, particularly those aimed at pancreatic cancer. With this acquisition, BMS intends to utilize its global scale and resources to accelerate the delivery of more effective treatments to cancer patients. Mirati Therapeutics, Inc. is a US-based biotech firm specializing in pancreatic cancer diagnosis.

Major companies operating in the pancreatic cancer diagnostic market include Pfizer Inc., Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation

North America was the largest region in the pancreatic cancer diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pancreatic cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic cancer diagnostic market includes revenues earned by entities through computerized tomography (CT) scans, Magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The pancreatic cancer diagnostic market consists of sales of tumor markers and drugs such as Abraxane, Afinitor, and Capecitabine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Diagnostic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer diagnostic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer diagnostic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Instruments; Consumables; Services
• 2) By Treatment: Surgery; Chemotherapy; Radiation Therapy; Targeted Therapy
• 3) By Cancer Type: Exocrine; Adenocarcinoma; Squamous Cell Carcinoma; Adenosquamous Carcinoma; Colloid Carcinoma; Endocrine
• 4) By Test Type: Imaging Test; Biopsy; Blood Test; Genomic Test; Other Test Types
• 5) By End-User: Hospitals; Diagnostic Centers; Cancer Research Centers; Academic Institutes; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Instruments: Imaging Systems; Biopsy Devices; Endoscopy Equipment
• 2) By Consumables: Reagents; Biopsy Needles; Assay Kits
• 3) By Services: Diagnostic Testing Services; Laboratory Services; Consulting Services
• Companies Mentioned: Pfizer Inc.; Hitachi Medical Corporation; F. Hoffmann-La Roche AG; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Diagnostic Market Characteristics

3. Pancreatic Cancer Diagnostic Market Trends And Strategies

4. Pancreatic Cancer Diagnostic Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pancreatic Cancer Diagnostic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pancreatic Cancer Diagnostic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pancreatic Cancer Diagnostic Market Growth Rate Analysis
• 5.4. Global Pancreatic Cancer Diagnostic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pancreatic Cancer Diagnostic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pancreatic Cancer Diagnostic Total Addressable Market (TAM)

6. Pancreatic Cancer Diagnostic Market Segmentation

• 6.1. Global Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instruments
• Consumables
• Services
• 6.2. Global Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• 6.3. Global Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine
• Adenocarcinoma
• Squamous Cell Carcinoma
• Adenosquamous Carcinoma
• Colloid Carcinoma
• Endocrine
• 6.4. Global Pancreatic Cancer Diagnostic Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Test
• Biopsy
• Blood Test
• Genomic Test
• Other Test Types
• 6.5. Global Pancreatic Cancer Diagnostic Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Cancer Research Centers
• Academic Institutes
• Ambulatory Surgical Centers
• Other End-Users
• 6.6. Global Pancreatic Cancer Diagnostic Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Systems
• Biopsy Devices
• Endoscopy Equipment
• 6.7. Global Pancreatic Cancer Diagnostic Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reagents
• Biopsy Needles
• Assay Kits
• 6.8. Global Pancreatic Cancer Diagnostic Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Testing Services
• Laboratory Services
• Consulting Services

7. Pancreatic Cancer Diagnostic Market Regional And Country Analysis

• 7.1. Global Pancreatic Cancer Diagnostic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pancreatic Cancer Diagnostic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pancreatic Cancer Diagnostic Market

• 8.1. Asia-Pacific Pancreatic Cancer Diagnostic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pancreatic Cancer Diagnostic Market

• 9.1. China Pancreatic Cancer Diagnostic Market Overview
• 9.2. China Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pancreatic Cancer Diagnostic Market

• 10.1. India Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pancreatic Cancer Diagnostic Market

• 11.1. Japan Pancreatic Cancer Diagnostic Market Overview
• 11.2. Japan Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pancreatic Cancer Diagnostic Market

• 12.1. Australia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pancreatic Cancer Diagnostic Market

• 13.1. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pancreatic Cancer Diagnostic Market

• 14.1. South Korea Pancreatic Cancer Diagnostic Market Overview
• 14.2. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pancreatic Cancer Diagnostic Market

• 15.1. Western Europe Pancreatic Cancer Diagnostic Market Overview
• 15.2. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pancreatic Cancer Diagnostic Market

• 16.1. UK Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pancreatic Cancer Diagnostic Market

• 17.1. Germany Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pancreatic Cancer Diagnostic Market

• 18.1. France Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pancreatic Cancer Diagnostic Market

• 19.1. Italy Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pancreatic Cancer Diagnostic Market

• 20.1. Spain Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pancreatic Cancer Diagnostic Market

• 21.1. Eastern Europe Pancreatic Cancer Diagnostic Market Overview
• 21.2. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pancreatic Cancer Diagnostic Market

• 22.1. Russia Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pancreatic Cancer Diagnostic Market

• 23.1. North America Pancreatic Cancer Diagnostic Market Overview
• 23.2. North America Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pancreatic Cancer Diagnostic Market

• 24.1. USA Pancreatic Cancer Diagnostic Market Overview
• 24.2. USA Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pancreatic Cancer Diagnostic Market

• 25.1. Canada Pancreatic Cancer Diagnostic Market Overview
• 25.2. Canada Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pancreatic Cancer Diagnostic Market

• 26.1. South America Pancreatic Cancer Diagnostic Market Overview
• 26.2. South America Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pancreatic Cancer Diagnostic Market

• 27.1. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pancreatic Cancer Diagnostic Market

• 28.1. Middle East Pancreatic Cancer Diagnostic Market Overview
• 28.2. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pancreatic Cancer Diagnostic Market

• 29.1. Africa Pancreatic Cancer Diagnostic Market Overview
• 29.2. Africa Pancreatic Cancer Diagnostic Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pancreatic Cancer Diagnostic Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pancreatic Cancer Diagnostic Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pancreatic Cancer Diagnostic Market Competitive Landscape And Company Profiles

• 30.1. Pancreatic Cancer Diagnostic Market Competitive Landscape
• 30.2. Pancreatic Cancer Diagnostic Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hitachi Medical Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Pancreatic Cancer Diagnostic Market Other Major And Innovative Companies

• 31.1. Thermo Fisher Scientific Inc.
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories Inc.
• 31.4. Danaher Corporation
• 31.5. Siemens Healthcare GmbH
• 31.6. FUJIFILM Corporation
• 31.7. Becton Dickinson and Company
• 31.8. Koninklijke Philips N.V.
• 31.9. GE Healthcare Bio Sciences AB
• 31.10. Laboratory Corporation of America Holdings
• 31.11. Agilent Technologies Inc.
• 31.12. Illumina Inc.
• 31.13. Qiagen Inc.
• 31.14. Myriad Genetics Inc.
• 31.15. Canon Medical Systems Corporation

32. Global Pancreatic Cancer Diagnostic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Cancer Diagnostic Market

34. Recent Developments In The Pancreatic Cancer Diagnostic Market

35. Pancreatic Cancer Diagnostic Market High Potential Countries, Segments and Strategies

• 35.1 Pancreatic Cancer Diagnostic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pancreatic Cancer Diagnostic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pancreatic Cancer Diagnostic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer